Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)

Table 2

Coagulation parameters of patient 1 in the setting of acalabrutinib-related subungual hematoma.

Parameters	Reference range	Initial	Follow-up (6 weeks after holding acalabrutinib)
PT	9.7–13.0 sec	12.5	12.5
APTT	23.0–32.4 sec	31.6	31.1
Platelet count	150–400 k/uL	171	122
Factor VIII	50–173%	135	106
VWF: Ag	50–173%	162	126
VWF: RCo	42–146%	76	76
VWF: CB	41–161%	91	72
FVIII/VWF ratio	>0.4	0.8	0.8
RCo/VWF ratio	>0.4	0.5	0.6
CB/VWF ratio	>0.5	0.6	0.6
Multimeric analysis
Low MW multimers	8.9–23.1%	41.1	34.7
Intermediate MW multimers	21.6–38.9%	34.6	32.5
High MW multimers	39.9–68.3%	24.3	32.8
IgM κ monoclonal protein	0 g/dL	0.41	0.33
IgM	40–230 mg/dL	638	505

vWF: von Willebrand factor, Ag: antigen, RCo: ristocetin cofactor, CB: collagen binding, and MW: molecular weight.